SEBI starts investigation into pharma scrips
Mumbai: The Securities and Exchange Board of India (SEBI) has launched a probe into the steep rise in pharmaceutical company scrips on the bourses. It has asked the bourses to furnish all trade information on stocks of pharmaceutical companies, including details on the identity of big buyers or sellers on these counters.

SEBI has also asked the exchanges to examine the trading pattern in these stocks to check for any evidence of rampant price manipulation in these counters. Bombay Stock Exchange officials were quoted as saying: "The exchange, on a regular basis, provides the regulator with a lot of data on trading patterns. This includes data relating to various sectors, including pharmaceuticals." In the past one month, the combined market capitalisation of 34 Indian bulk drugs and formulations companies surged 22.7 per cent to around Rs 50,320 crore.
Back to News Review index page  

Debt funds bright on rate hopes
Mumbai: Debt fund managers are working with zeal to make profits out of the stagnant interest rates. A way they have adopted is through creating innovative products.

The path less travelled is to tweak some features of existing products so as to enable the same portfolio perform better when the industry consensus is that interest rates will not fall much further, reports say.
Back to News Review index page  

BSE to shift 555 stocks to Z category
Mumbai: The Bombay Stock Exchange (BSE) has said the 555 stocks that will be shifted to the Z category, effective today, have already impacted the trading volumes and the prices of these stocks.

Of the 555 stocks to be shifted to the Z group from today, 518 are actively traded on the BSE, while as many as 26 scrips have not been traded during the last two days. The remaining 11 scrips were not traded in the last 15 days.
Back to News Review index page